DK0463969T3 - Hidtil ukendte 4-aminosmørsyreforbindelser, fremgangsmåde til fremstilling heraf og farmaceutiske præparater, som indeholder dem - Google Patents

Hidtil ukendte 4-aminosmørsyreforbindelser, fremgangsmåde til fremstilling heraf og farmaceutiske præparater, som indeholder dem

Info

Publication number
DK0463969T3
DK0463969T3 DK91401739.7T DK91401739T DK0463969T3 DK 0463969 T3 DK0463969 T3 DK 0463969T3 DK 91401739 T DK91401739 T DK 91401739T DK 0463969 T3 DK0463969 T3 DK 0463969T3
Authority
DK
Denmark
Prior art keywords
radical
optionally substituted
atom
nitrogen
carbon
Prior art date
Application number
DK91401739.7T
Other languages
English (en)
Inventor
Michel Debaert
Pascal Berthelot
Claude Vaccher
Original Assignee
Adir
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adir filed Critical Adir
Application granted granted Critical
Publication of DK0463969T3 publication Critical patent/DK0463969T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28—Halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Indole Compounds (AREA)
DK91401739.7T 1990-06-27 1991-06-27 Hidtil ukendte 4-aminosmørsyreforbindelser, fremgangsmåde til fremstilling heraf og farmaceutiske præparater, som indeholder dem DK0463969T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9008093A FR2663934B1 (fr) 1990-06-27 1990-06-27 Nouveaux derives de l'acide 4 - amino butyrique, leur procede de preparation et les preparations pharmaceutiques qui les contiennent.

Publications (1)

Publication Number Publication Date
DK0463969T3 true DK0463969T3 (da) 1995-07-10

Family

ID=9398069

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91401739.7T DK0463969T3 (da) 1990-06-27 1991-06-27 Hidtil ukendte 4-aminosmørsyreforbindelser, fremgangsmåde til fremstilling heraf og farmaceutiske præparater, som indeholder dem

Country Status (15)

Country Link
US (2) US5162364A (da)
EP (1) EP0463969B1 (da)
JP (1) JPH04243853A (da)
AT (1) ATE118213T1 (da)
AU (1) AU637242B2 (da)
CA (1) CA2045445A1 (da)
DE (1) DE69107250T2 (da)
DK (1) DK0463969T3 (da)
ES (1) ES2071250T3 (da)
FR (1) FR2663934B1 (da)
GR (1) GR3015796T3 (da)
IE (1) IE65593B1 (da)
OA (1) OA09373A (da)
PT (1) PT98100A (da)
ZA (1) ZA914969B (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004532A1 (en) * 1992-08-19 1994-03-03 Mcneilab, Inc. 3-oxo-pyrido(1,2-a^_)benzimidazole-4-carboxyl and 4-oxo-azepino(1,2-a^_)benzimidazole-5-carboxyl derivatives useful in treating central nervous system disorders
US6489355B2 (en) * 1993-12-01 2002-12-03 Eli Lilly And Company Methods of inhibiting the effects of amyloidogenic proteins
FR2722192A1 (fr) * 1994-07-06 1996-01-12 Adir Nouveaux derives de l'acide 4-amino butyrique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9906882D0 (en) * 1999-03-25 1999-05-19 Novartis Ag Organic compounds
SE9904507D0 (sv) 1999-12-09 1999-12-09 Astra Ab New compounds
US7319095B2 (en) 1999-12-09 2008-01-15 Astrazeneca Ab Use of GABAB receptor agonists
SE9904508D0 (sv) 1999-12-09 1999-12-09 Astra Ab New compounds
AR033779A1 (es) * 2001-06-08 2004-01-07 Astrazeneca Ab Compuestos utiles en la enfermedad de reflujo
KR20110097942A (ko) 2003-08-20 2011-08-31 제노포트 인코포레이티드 아실옥시알킬 카르바메이트 프로드러그, 합성 및 사용 방법
EP2354120A1 (en) 2003-08-20 2011-08-10 XenoPort, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
EP1691811B1 (en) 2003-12-11 2014-07-23 Sunovion Pharmaceuticals Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
SE0401653D0 (sv) * 2004-06-24 2004-06-24 Astrazeneca Ab New compounds
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
AU2006327317B2 (en) 2005-12-23 2010-11-25 Astrazeneca Ab GABA-B receptor modulators
CN101341130A (zh) * 2005-12-23 2009-01-07 阿斯利康(瑞典)有限公司 用于治疗胃肠障碍的咪唑衍生物
US20090062365A1 (en) * 2005-12-23 2009-03-05 Udo Bauer Pyrazoles for the Treatment of GERD and IBS
BRPI0620345A2 (pt) * 2005-12-23 2017-11-21 Astrazeneca Ab composto, composição farmacêutica, uso de um composto, e, métodod para o tratamento de uma doença
BRPI0620373A2 (pt) * 2005-12-23 2011-11-08 Astrazeneca Ab composto e sais farmaceuticamente e farmacologicamente aceitáveis dos mesmos, e enantiÈmeros do composto e sais dos mesmos, uso dos mesmos, opcionalmente em combinação com um agonista do receptor de gabab,e , composição farmaceutica
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008130314A1 (en) * 2007-04-18 2008-10-30 Astrazeneca Ab Xanthine compounds having a positive allosteric gabab receptor modulator effect
WO2008130313A1 (en) * 2007-04-18 2008-10-30 Astrazeneca Ab Imidazole derivatives as modulators of the gaba receptor for the treatment of gastrointestinal disorders
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
WO2011113904A1 (en) 2010-03-17 2011-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Medicaments for the prevention and treatment of a disease associated with retinal ganglion cell degeneration
WO2012050907A2 (en) 2010-09-28 2012-04-19 The Regents Of The University Of California Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4940460B1 (da) * 1971-08-28 1974-11-02
US4328214A (en) * 1979-07-04 1982-05-04 Ciba-Geigy Corporation Cyclopeptides and pharmaceutical preparations thereof and also processes for their manufacture
ZA804008B (en) * 1979-07-04 1981-06-24 Ciba Geigy New cyclopeptides and pharmaceutical preparations thereof and also processes for their manufacture
US4581167A (en) * 1982-01-19 1986-04-08 Research Corporation Peptide synthesis and amino acid blocking agents
DE3241512A1 (de) * 1982-11-10 1984-05-10 Bayer Ag, 5090 Leverkusen Substituierte malonsaeurediamide, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel
JP2561478B2 (ja) * 1986-07-22 1996-12-11 武田薬品工業株式会社 グリセリン誘導体
GB8707412D0 (en) * 1987-03-27 1987-04-29 Fujisawa Pharmaceutical Co Peptide compounds
US5047540A (en) * 1987-12-17 1991-09-10 Shionogi & Co., Ltd. Lipid derivatives

Also Published As

Publication number Publication date
AU637242B2 (en) 1993-05-20
CA2045445A1 (fr) 1991-12-28
DE69107250T2 (de) 1995-09-21
ES2071250T3 (es) 1995-06-16
PT98100A (pt) 1992-03-31
IE65593B1 (en) 1995-11-01
JPH04243853A (ja) 1992-08-31
US5278166A (en) 1994-01-11
ZA914969B (en) 1992-04-29
EP0463969B1 (fr) 1995-02-08
US5162364A (en) 1992-11-10
GR3015796T3 (en) 1995-07-31
DE69107250D1 (de) 1995-03-23
ATE118213T1 (de) 1995-02-15
IE912224A1 (en) 1992-01-01
AU7929491A (en) 1992-01-02
FR2663934A1 (fr) 1992-01-03
FR2663934B1 (fr) 1994-06-03
EP0463969A1 (fr) 1992-01-02
OA09373A (fr) 1992-09-15

Similar Documents

Publication Publication Date Title
DK0463969T3 (da) Hidtil ukendte 4-aminosmørsyreforbindelser, fremgangsmåde til fremstilling heraf og farmaceutiske præparater, som indeholder dem
DK0530087T3 (da) Hidtil ukendte naphthylethylurinstof- og naphthylethylthiourinstofforbindelser, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
DE3576690D1 (de) Pyrimidopyrimidinderivate, verfahren zu ihrer herstellung, diese enthaltende pharmazeutische zubereitungen und ihre verwendung als anti-allergische mittel.
NO833942L (no) Beta-karboliner, fremgangsmaate til deres fremstilling og farmasoeytiske preparater som inneholder dem
ATE69239T1 (de) Oligopeptidylnitrilderivate, diese enthaltende mittel, verfahren zu ihrer herstellung und ihre verwendung.
DE68928644D1 (de) Heterocyclische Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
ZA911402B (en) Aminomethylpiperidine derivatives,process for preparing these and pharmaceutical compositions containing them
PT83535B (pt) Processo para a preparacao de composicoes farmaceuticas contendo derivados de aminoacidos
NO302072B1 (no) Azabicyklo-arylacetylen- og -arylenyn-oksimer som cholinerge midler og preparater inneholdende slike
ATE48001T1 (de) Cephemverbindungen, verfahren zu ihrer herstellung und ihre pharmazeutischen praeparate.
DK159441C (da) 11-substituerede 5,11-dihydro-6h-dibenz(b,e)azepin-6-on-derivater, laegemidler indeholdende disse forbindelser og analogifremgangsmaade til forbindelsernes fremstilling
DK235889D0 (da) Derivater af 6-phenyl-3-piperazinylalkyl-1h,3h-pyrimidindion-2,4, fremgangsmaade til fremstilling af saadanne forbindelser og laegemiddel indeholdende disse
DK611087D0 (da) Fremgangsmaade til fremstilling af mono-, di- og tricycliske aminosyrer samt mellemprodukter til denne fremgangsmaade og en fremgangsmaade til deres fremstilling
DK0452204T3 (da) Hidtil ukendte 3-aminochromanderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
ES544417A0 (es) Procedimiento para preparar 8-alquiltio-2-piperazino-pirimido(5,4-d)pirimidinas.
DK0486385T3 (da) Imidazolderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
DK0736009T3 (da) N-oxider af 4-arylpiperaziner og 4-arylpiperidiner som antipsykotiske medikamenter
DK389784D0 (da) Acylerede enamider og farmaceutiske praeparater der indeholder dem
DK0612763T3 (da) Cykliske angiopeptinderivater, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
DK356287D0 (da) 2,6-piperazindionderivater, fremgangsmaade til fremstilling deraf og farmaceutiske praeparater indeholdende disse
DE3883434D1 (de) Mitomycinanaloge, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitungen.
ES2102774T3 (es) Indolsulfonamidas como agentes antitumorales.
DK433383A (da) Fremgangsmaade til fremstilling af vinylcarbamater og hidtil ukendte vinylcarbamater
DK0650953T3 (da) Cykliske analoger af fedtsyremetabolitter, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som omfatter dem
ES476232A1 (es) Procedimiento para la obtencion de derivados del fosfonilu- reidobenceno.